The Year in Cardiology 2013: Coronary intervention

European Heart Journal

Volumn 35, Issue 5, 2014, Pages 313-320

  Erbel, Raimund ^a   Wijns, William ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Coronary intervention; Intervention; Interventional cardiology; PCI

Indexed keywords

CORONARY INTERVENTION; INTERVENTION; INTERVENTIONAL CARDIOLOGY; PCI;

CARDIOLOGY; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; INTRA-AORTIC BALLOON PUMPING; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STENTS; TISSUE SCAFFOLDS;

EID: 84893859472     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht550     Document Type: Review

References (55)

1. JonesDA, Gallagher S, Rathod K, Jain AK, Mathur A, Uppal R,Westwood M,Wong K, Rothman MT, Shipolini A, Smith EJ, Mills PG, Timmis AD, Knight CJ, Archbold RA, Wragg A. Clinical outcomes after myocardial revascularization according to operator training status: Cohort study of 22 697 patients undergoing percutaneous coronary intervention or coronary artery bypass graft surgery. Eur Heart J 2013;34: 2887-2895.
2. Cates CU, Gallagher AG. The future of simulation technologies for complex cardiovascular procedures. Eur Heart J 2012;33:2127-2134.
3. Chan PS, Patel MR, Klein LW, Krone RJ, Dehmer GJ, Kennedy K, Nallamothu BK, Weaver WD, Masoudi FA, Rumsfeld JS, Brindis RG, Spertus JA. Appropriateness of percutaneous coronary intervention. JAMA 2011;306:53-61.
4. Calvert PA, Steg PG. Towards evidence-based percutaneous coronary intervention: The René Laënnec lecture in clinical cardiology. Eur Heart J 2012;33:1878-1885.
5. Li J, Elrashidi MY, Flammer AJ, Lennon RJ, Bell MR, Holmes DR, Bresnahan JF, Rihal CS, Lerman LO, Lerman A. Long-term outcomes of fractional flow reserveguided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J 2013;34:1375-1383.
6. Park SJ, Ahn JM, ParkGM, Cho YR, Lee JY, Kim WJ, Han S, Kang SJ, ParkDW, LeeSW, Kim YH, LeeCW, Mintz GS, ParkSW. Trends in the outcomes of percutaneous coronary intervention with the routine incorporation of fractional flow reserve in real practice. Eur Heart J 2013;34:3353-3361.
7. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, Budaj A, Niemela M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, Chrolavicius S, Mehta SR, RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): A randomised, parallel group, multicentre trial. Lancet 2011;377: 1409-1420.
8. Jolly SS, Cairns J, Niemela K, Steg PG, Natarajan MK, Cheema AN, Rao SV, Cantor WJ, Dz?avík V, Budaj A, Sheth T, Valentin V, Fung A, Widimsky P, Ferrari E, Gao P, Jedrzejowski B, Mehta SR, RIVAL Investigators. Effect of radial versus femoral access on radiation dose and the importance of procedural volume: A substudy of the multicenter randomized RIVAL trial. JACC Cardiovasc Interv 2013;6: 258-266.
9. Kiemeneij F, Laarman GJ, Slagboom T, van Der Wieken R. Outpatient coronary stent implantation. J Am Coll Cardiol 1997;29:323-327.
10. Muthusamy P, Busman DK, Davis AT,Wohns DH. Assessment of clinical outcomes related to early discharge after elective percutaneous coronary intervention:COED PCI. Catheter Cardiovasc Interv 2013;81:6-13.
11. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur J Cardiothoracic Surg 2010;38(Suppl.):S1-S52.
12. FarooqV, VergouweY, Räber L, Vranckx P, Garcia-Garcia H, Diletti R, Kappetein AP, Morel MA, de Vries T, Swart M, Valgimigli M, Dawkins KD, Windecker S, Steyerberg EW, SerruysPW. Combined anatomical and clinical factors for the longterm risk stratification of patients undergoing percutaneous coronary intervention: The Logistic Clinical SYNTAX score. Eur Heart J 2012;33:3098-3104.
13. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, Colombo A, Holmes DR Jr, Mack M, Feldman T, Morice MC, Ståhle E, Onuma Y, Morel MA, Garcia-Garcia HM, van Es GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: Development and validation of SYNTAX score II. Lancet 2013;381:639-650.
14. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/ ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Circulation 2012;126:2020-2035.
15. Park DW, Kim YH, Yun SC, Ahn JM, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ. Frequency, causes, predictors, and clinical significance of periprocedural myocardial infarction following percutaneous coronary intervention. Eur Heart J 2013;34:1662-1669.
16. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629-638.
17. Farooq V, Serruys PW, Bourantas C, Vranckx P, Diletti R, Garcia Garcia HM, Holmes DR, Kappetein AP, Mack M, Feldman T, Morice MC, Colombo A, Morel MA, de Vries T, van Es GA, Steyerberg EW, Dawkins KD, Mohr FW, James S, Ståhle E. Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. Eur Heart J 2012;33:3105-3113.
18. Garzillo CL, Hueb W, Gersh BJ, Lima EG, Rezende PC, Hueb AC, Vieira RD, Favarato D, Pereira AC, Soares PR, Serrano CV Jr, Ramires JA, Kalil Filho R. Longterm analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial. Eur Heart J 2013;34:3370-3377.
19. Head SJ, Kaul S, Mack MJ, SerruysPW, Taggart DP, Holmes DR Jr, Leon MB, Marco J, Bogers AJ, Kappetein AP. The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. Eur Heart J 2013;34:2510-2518.
20. Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of drug-eluting stents in women: A patient-level pooled analysis of randomised trials. Lancet 2013. [Epub ahead of print].
21. Patel VG, Brayton KM, Tamayo A, Mogabgab O, Michael TT, Lo N, Alomar M, Shorrock D, Cipher D, Abdullah S, Banerjee S, Brilakis ES. Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: A weighted meta-Analysis of 18,061 patients from 65 studies. JACC Cardiovasc Interv 2013;6:128-136.
22. Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33: 2569-2619.
23. Vlaar PJ, Svilaas T, van Der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): A 1-year follow-up study. Lancet 2008;371:1915-1920.
24. Noman A, Egred M, Bagnall A, Spyridopoulos I, Jamieson S, Ahmed J. Impact of thrombus aspiration during primary percutaneous coronary intervention on mortality in ST-segment elevation myocardial infarction. Eur Heart J 2012;33:3054-3061.
25. Onuma Y, Thuesen L, van Geuns RJ, van Der Ent M, Desch S, Fajadet J, Christiansen E, Smits P, Holm NR, Regar E, van Mieghem N, Borovicanin V, Paunovic D, Senshu K, van Es GA, Muramatsu T, Lee IS, Schuler G, Zijlstra F, Garcia-Garcia HM, Serruys PW, TROFI Investigators. Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: An optical frequency domain imaging study-TROFI trial. Eur Heart J 2013;34: 1050-1060.
26. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angerås O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, Johansson AC, Kåregren A, Nilsson J, Robertson L, Sandhall L, Sjögren I, Ostlund O, Harnek J, James SK. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013;369:1587-1597.
27. Porto I, Biasucci LM, De Maria GL, Leone AM, Niccoli G, Burzotta F, Trani C, Tritarelli A, Vergallo R, Liuzzo G, Crea F. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur Heart J 2012;33:2928-2938.
28. Robbers LF, Eerenberg ES, Teunissen PF, Jansen MF, Hollander MR, Horrevoets AJ, Knaapen P, Nijveldt R, Heymans MW, Levi MM, van Rossum AC, Niessen HW, Marcu CB, Beek AM, van Royen N. Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage. Eur Heart J 2013;34:2346-2353.
29. Heusch G, Kleinbongard P, Bö seD, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: From bedside to bench and back to bedside. Circulation 2009; 120:1822-1836.
30. Frö hlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: Looking beyond primary PCI. Eur Heart J 2013;34:1714-1722.
31. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG, PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013;369:1115-1123.
32. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, deWaha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Böhm M, Ebelt H, Schneider S, Werdan K, Schuler G, Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) Trial Investigators. Intra-Aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): Final 12 month results of a randomised, open-label trial. Lancet 2013;382:1638-1645.
33. Heusch G. Cardioprotection: Chances and challenges of its translation to the clinic. Lancet 2013;381:166-175.
34. Zhou C, Yao Y, Zheng Z, Gong J,WangW,HuS, Li L. Stenting technique, gender, and age are associated with cardioprotection by ischaemic postconditioning in primary coronary intervention: A systematic reviewof 10 randomized trials. Eur Heart J 2012; 33:3070-3077.
35. Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, Pedersen L, Sørensen HT, Bøtker HE, CONDI Investigators. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 2013. [Epub ahead of print].
36. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Säd SA, Kleijne MA, Sen H, Löwik MM, van Der Palen J, Verhorst PM, deManFH.Arandomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: The TWENTE trial. J Am Coll Cardiol 2012;59:1350-1361.
37. Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, Stoel MG, van Houwelingen KG, de Man FH, Linssen GC, Säd SA, Nienhuis MB, Löwik MM, Verhorst PM, van Der Palen J, von Birgelen C. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimuseluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. J Am Coll Cardiol 2013;61:2406-2416.
38. von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Säd SA, Nienhuis MB, Verhorst PM, BasalusMW, Doggen CJ, Tandjung K. Third-generation zotarolimus-eluting and everolimuseluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): A randomised, single-blind, multicentre, non-inferiority trial. Lancet 2013. [Epub ahead of print].
39. Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P. RESOLUTE All Comers; RESOLUTE International Investigators. Clinical outcomes of the resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. JACC Cardiovasc Interv 2013;6:905-913.
40. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, WijnsW, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimuseluting stents in patients with coronary artery disease: Final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv 2013;6:777-789.
41. Smits PC, Hofma S, Togni M, Vázquez N, Valdés M, Voudris V, Slagboom T, Goy JJ, Vuillomenet A, Serra A, Nouche RT, den Heijer P, van Der Ent M. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimuseluting stent (COMPARE II): A randomised, controlled, non-inferiority trial. Lancet 2013;381:651-660.
42. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T, NEXT Investigators. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: A randomized, controlled, noninferiority trial. J Am Coll Cardiol 2013;68:181-190.
43. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R, Mauri L, Meredith IT, Finn AV, Kim HS, Kubica J, Suryapranata H, Aprami TM, Di Pasquale G, von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: Comprehensive network meta-Analysis. BMJ 2013. [Epub ahead of print].
44. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: A meta-Analysis of randomized trials. Eur Heart J 2012;33:3078-3087.
45. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R. PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J 2013;34:909-919.
46. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmão M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL, OPTIMIZE Trial Investigators. Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus- Eluting Stents: The OPTIMIZE Randomized Trial. JAMA 2013. [Epub ahead of print].
47. Charlot M, Nielsen LH, Lindhardsen J, Ahlehoff O, Olsen AM, Hansen ML, Hansen PR, Madsen JK, Køber L, Gislason GH, Torp-Pedersen C. Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: A nationwide cohort study. Eur Heart J 2012;33:2527-2534.
48. Mehran R, Baber U, Steg PG, Ariti C,Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013. [Epub ahead of print].
49. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys PW. Bioresorbable Scaffolds: Rationale, current status, challenges and future. Eur H J 2013. [Epub ahead of print].
50. Gori T, Schulz E, Hink U,Wenzel P, Post F, Jabs A, Münzel T. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2013. [Epub ahead of print].
51. Kocka V, Malyy M, Budesínskyy T, Lisa L, Prodanov P, Tousek P, Jarkovskyy J, Widimsky P. Bioresorbable vascular scaffolds in acute ST- segment elevation myocardial infarction. A prospective multicenter study: PRAGUE 19. Eur Heart J 2013. [Epub ahead of print].
52. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, SerruysPW, Zijlstra F, van Geuns RJ. Everolimus eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction. BVS STEMI FIRST Study. Eur Heart J 2013. [Epub ahead of print].
53. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, Ormiston JA, Serruys PW. Five-Year Clinical and Functional Multislice Computed Tomography Angiographic Results After Coronary Implantation of the Fully Resorbable Polymeric Everolimus-Eluting Scaffold in Patients With De Novo Coronary Artery Disease: The ABSORB Cohort A Trial. JACC Cardiovasc Interv 2013;6: 999-1009.
54. Haude M, Erbel R, Erne P, Verheye S, Degen H, Bö seD, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381:836-844.
55. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, BhatV, Yan J, AbizaidA.ANext- Generation Bioresorbable Coronary Scaffold System-From Bench to First Clinical Evaluation: Six- and 12-Month Clinical and Multimodality Imaging Results. JACC Cardiovasc Interv 2013. [Epub ahead of print].